RSS Viracta Therapeutics Engages In Strategic Alternatives, Closes NAVAL-1 Trial

Currently reading:
 RSS Viracta Therapeutics Engages In Strategic Alternatives, Closes NAVAL-1 Trial

Status
Not open for further replies.

Crax Bot

Staff member
Administrator
Amateur
LV
0
Joined
Nov 5, 2021
Threads
7,268
Likes
1,920
Credits
32,994©
Cash
0$
Viracta Therapeutics Inc. (VIRX) has announced that it is currently exploring strategic alternatives with the intention of enhancing value. These potential alternatives include possibilities such as a merger, licensing agreement, sale, or other strategic transactions.

The company cautioned that there is no guarantee that this exploration will result in any specific agreements or transactions, nor can the timing of any potential outcomes be predicted.

Additionally, Viracta has decided to terminate its ongoing pivotal Phase 2 clinical trial of Nana-val, which was being conducted on patients with relapsed/refractory EBV+ lymphomas (NAVAL-1 trial). The company clarified that the decision to close the trial was made voluntarily and is not due to any newly identified safety concerns.

The material has been provided by InstaForex Company - www.instaforex.com
 
Status
Not open for further replies.
Tips

Similar threads

Top Bottom